Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$15.55 USD
+0.82 (5.57%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $15.56 +0.01 (0.06%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Arcus Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 759 | 1,009 | 499 | 729 | 188 |
Receivables | 38 | 39 | 747 | 2 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 34 | 19 | 16 | 5 | 4 |
Total Current Assets | 831 | 1,067 | 1,262 | 736 | 193 |
Net Property & Equipment | 51 | 35 | 32 | 11 | 9 |
Investments & Advances | 107 | 129 | 182 | 6 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 106 | 114 | 11 | 6 | 1 |
Total Assets | 1,095 | 1,345 | 1,592 | 772 | 203 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 17 | 20 | 10 | 16 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 54 | 28 | 10 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 167 | 173 | 102 | 78 | 8 |
Total Current Liabilities | 184 | 193 | 166 | 122 | 23 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 307 | 355 | 462 | 123 | 12 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 142 | 140 | 5 | 10 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 633 | 688 | 750 | 270 | 39 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1,311 | 1,206 | 0 | 0 | 0 |
Capital Surplus | 0 | 0 | 1,118 | 830 | 369 |
Retained Earnings | -849 | -542 | -275 | -328 | -205 |
Other Equity | 0 | -7 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 462 | 657 | 841 | 502 | 164 |
Total Liabilities & Shareholder's Equity | 1,095 | 1,345 | 1,592 | 772 | 203 |
Total Common Equity | 462 | 657 | 841 | 502 | 164 |
Shares Outstanding | 74.80 | 72.40 | 70.20 | 64.90 | 45.80 |
Book Value Per Share | 6.18 | 9.07 | 11.99 | 7.74 | 3.58 |
Fiscal Year End for Arcus Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 759 | 799 | 930 | 954 |
Receivables | NA | 38 | 52 | 34 | 33 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 34 | 31 | 22 | 28 |
Total Current Assets | NA | 831 | 882 | 986 | 1,015 |
Net Property & Equipment | NA | 51 | 50 | 45 | 37 |
Investments & Advances | NA | 107 | 151 | 80 | 90 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 106 | 108 | 109 | 112 |
Total Assets | NA | 1,095 | 1,191 | 1,220 | 1,254 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 17 | 17 | 12 | 28 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 167 | 183 | 168 | 151 |
Total Current Liabilities | NA | 184 | 200 | 180 | 179 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 307 | 326 | 330 | 330 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 145 | 144 | 145 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 633 | 671 | 654 | 654 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1,311 | 1,291 | 1,267 | 1,226 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | -849 | -768 | -697 | -622 |
Other Equity | NA | 0 | -3 | -4 | -4 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 462 | 520 | 566 | 600 |
Total Liabilities & Shareholder's Equity | NA | 1,095 | 1,191 | 1,220 | 1,254 |
Total Common Equity | 0 | 462 | 520 | 566 | 600 |
Shares Outstanding | 90.80 | 74.80 | 74.50 | 73.10 | 73.00 |
Book Value Per Share | 0.00 | 6.18 | 6.98 | 7.74 | 8.22 |